It has been demonstrated that treatment with anti-VEGF drugs leads to an increase in IL-17 in the tumor micro-environment, which initiates a paracrine network that elicits an angiogenic response independently of VEGF and thus contributes to drug resistance (Chung et al., 2013). The gene discussed is IL17A; the disease is neoplasm.